187 related articles for article (PubMed ID: 25123543)
1. Adverse event reporting in nonpharmacologic, noninterventional pain clinical trials: ACTTION systematic review.
Hunsinger M; Smith SM; Rothstein D; McKeown A; Parkhurst M; Hertz S; Katz NP; Lin AH; McDermott MP; Rappaport BA; Turk DC; Dworkin RH
Pain; 2014 Nov; 155(11):2253-62. PubMed ID: 25123543
[TBL] [Abstract][Full Text] [Related]
2. Adverse Event Reporting in Clinical Trials of Intravenous and Invasive Pain Treatments: An ACTTION Systematic Review.
Williams MR; McKeown A; Pressman Z; Hunsinger M; Lee K; Coplan P; Gilron I; Katz NP; McDermott MP; Raja SN; Rappaport BA; Rowbotham MC; Turk DC; Dworkin RH; Smith SM
J Pain; 2016 Nov; 17(11):1137-1149. PubMed ID: 27522950
[TBL] [Abstract][Full Text] [Related]
3. Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations.
Smith SM; Wang AT; Katz NP; McDermott MP; Burke LB; Coplan P; Gilron I; Hertz SH; Lin AH; Rappaport BA; Rowbotham MC; Sampaio C; Sweeney M; Turk DC; Dworkin RH
Pain; 2013 Jul; 154(7):997-1008. PubMed ID: 23602344
[TBL] [Abstract][Full Text] [Related]
4. Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review.
Smith SM; Chang DR; Pereira A; Shah N; Gilron I; Katz NP; Lin AH; McDermott MP; Rappaport BA; Rowbotham MC; Sampaio C; Turk DC; Dworkin RH
Pain; 2012 Dec; 153(12):2415-2421. PubMed ID: 22985899
[TBL] [Abstract][Full Text] [Related]
5. Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Cannabinoids for Chronic Pain: Protocol for a Systematic Review.
Mohiuddin MM; Mizubuti G; Haroutounian S; Smith S; Campbell F; Park R; Gilron I
JMIR Res Protoc; 2019 Jan; 8(1):e11637. PubMed ID: 30688655
[TBL] [Abstract][Full Text] [Related]
6. Adverse Events Reported in Trials Assessing Manual Therapy to the Extremities: A Systematic Review.
Ferguson J; Fritsch A; Rhon DI; Young JL
J Integr Complement Med; 2024 Jun; 30(6):507-517. PubMed ID: 38452161
[No Abstract] [Full Text] [Related]
7. Adverse event assessment and reporting in trials of newer treatments for post-operative pain.
Hoffer D; Smith SM; Parlow J; Allard R; Gilron I
Acta Anaesthesiol Scand; 2016 Aug; 60(7):842-51. PubMed ID: 26991481
[TBL] [Abstract][Full Text] [Related]
8. Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain: A Systematic Review.
Mohiuddin MM; Mizubuti GB; Haroutounian S; Smith SM; Rice ASC; Campbell F; Park R; Gilron I
Clin J Pain; 2020 Apr; 36(4):302-319. PubMed ID: 31977375
[TBL] [Abstract][Full Text] [Related]
9. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.
Péron J; Maillet D; Gan HK; Chen EX; You B
J Clin Oncol; 2013 Nov; 31(31):3957-63. PubMed ID: 24062406
[TBL] [Abstract][Full Text] [Related]
10. Reporting of adverse events and statistical details of efficacy estimates in randomized clinical trials of pain in temporomandibular disorders: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks systematic review.
Gewandter JS; Smith SM; McKeown A; Edwards K; Narula A; Pawlowski JR; Rothstein D; Desjardins PJ; Dworkin SF; Gross RA; Ohrbach R; Rappaport BA; Sessle BJ; Turk DC; Dworkin RH
J Am Dent Assoc; 2015 Apr; 146(4):246-54.e6. PubMed ID: 25819656
[TBL] [Abstract][Full Text] [Related]
11. Identification, collection, and reporting of harms among non-industry-sponsored randomized clinical trials of pharmacologic interventions in the critically ill population: a systematic review.
Moskowitz A; Andersen LW; Holmberg MJ; Grossestreuer AV; Berg KM; Granfeldt A
Crit Care; 2020 Jul; 24(1):398. PubMed ID: 32641148
[TBL] [Abstract][Full Text] [Related]
12. Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review.
Chowers MY; Gottesman BS; Leibovici L; Pielmeier U; Andreassen S; Paul M
J Antimicrob Chemother; 2009 Aug; 64(2):239-50. PubMed ID: 19477890
[TBL] [Abstract][Full Text] [Related]
13. Deficiencies in reporting of statistical methodology in recent randomized trials of nonpharmacologic pain treatments: ACTTION systematic review.
Dworkin JD; McKeown A; Farrar JT; Gilron I; Hunsinger M; Kerns RD; McDermott MP; Rappaport BA; Turk DC; Dworkin RH; Gewandter JS
J Clin Epidemiol; 2016 Apr; 72():56-65. PubMed ID: 26597977
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of adverse event reporting in companion animal clinical trials evaluating cancer treatment.
Giuffrida MA
J Am Vet Med Assoc; 2016 Nov; 249(9):1079-1087. PubMed ID: 27767430
[TBL] [Abstract][Full Text] [Related]
15. Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events.
Mayo-Wilson E; Fusco N; Hong H; Li T; Canner JK; Dickersin K
Trials; 2019 Sep; 20(1):553. PubMed ID: 31488200
[TBL] [Abstract][Full Text] [Related]
16. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.
Basch E; Rogak LJ; Dueck AC
Clin Ther; 2016 Apr; 38(4):821-30. PubMed ID: 27045992
[TBL] [Abstract][Full Text] [Related]
17. Reporting of sample size calculations in analgesic clinical trials: ACTTION systematic review.
McKeown A; Gewandter JS; McDermott MP; Pawlowski JR; Poli JJ; Rothstein D; Farrar JT; Gilron I; Katz NP; Lin AH; Rappaport BA; Rowbotham MC; Turk DC; Dworkin RH; Smith SM
J Pain; 2015 Mar; 16(3):199-206.e1-7. PubMed ID: 25481494
[TBL] [Abstract][Full Text] [Related]
18. Analysis and reporting of adverse events in randomised controlled trials: a review.
Phillips R; Hazell L; Sauzet O; Cornelius V
BMJ Open; 2019 Mar; 9(2):e024537. PubMed ID: 30826796
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
Honvo G; Bannuru RR; Bruyère O; Rannou F; Herrero-Beaumont G; Uebelhart D; Cooper C; Arden N; Conaghan PG; Reginster JY; Thomas T; McAlindon T
Drugs Aging; 2019 Apr; 36(Suppl 1):145-159. PubMed ID: 31073927
[TBL] [Abstract][Full Text] [Related]
20. Adverse event methods were heterogeneous and insufficiently reported in randomized trials on persistent depressive disorder.
Meister R; von Wolff A; Mohr H; Nestoriuc Y; Härter M; Hölzel L; Kriston L
J Clin Epidemiol; 2016 Mar; 71():97-108. PubMed ID: 26482955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
